Last updated: 2026-09-08 09:47:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $11.14, with a market capitalization of $214.30M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.12 to $20.56. This page covers its latest market performance, valuation, price trends and company information.
$214.30M | |
$11.14 | |
$323.40 | |
$2.11 | |
-- | |
155.00 | |
429.37K | |
-- | |
$20.56 | |
$7.12 | |
-- | |
-- |
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is trading at $11.42 in pre-market trading as of 2026-09-08 08:33:00, -- from the previous close of $0.00
Pre-market trading shows how investors are pricing CRBP before the regular session opens. The current pre-market price is -- the previous close, indicating positive early trading sentiment.
Over the past seven days, Corbus Pharmaceuticals Holdings, Inc. (CRBP) moved from $11.13 to $11.14, representing a gain of 0.04% ($0.00).
The stock traded between $10.39 and $11.60 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 521.07 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 29.9%
CRBP is currently trading at $11.14, placing it 29.9% of the way from its 52-week low of $7.12 to its 52-week high of $20.56. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 36 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.